Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.
Zengin Z, Salgia N, Chehrazi-Raffle A, Meza L, Malhotra J, Pal S. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. The Cancer Journal 2020, 26: 432-440. PMID: 32947311, DOI: 10.1097/ppo.0000000000000473.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsMetastatic renal cell carcinomaRenal cell carcinomaCheckpoint inhibitorsAdverse eventsCell carcinomaDeath ligand 1 (PD-L1) immune checkpoint inhibitorsAnti-programmed death-1/Common immune-related adverse eventsImmune-related adverse eventsPivotal phase III trialsPrevious treatment optionsPhase III trialsDeath-1/Advanced kidney cancerRecent therapeutic advancementsUnique toxicity profileDrug Administration approvalFrontline regimensIII trialsClinical outcomesTreatment optionsRare toxicityAdministration approvalTargeted therapyTivozanib in renal cell carcinoma: a new approach to previously treated disease
Salgia N, Zengin Z, Pal S. Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances In Medical Oncology 2020, 12: 1758835920923818. PMID: 32547647, PMCID: PMC7249546, DOI: 10.1177/1758835920923818.Peer-Reviewed Original ResearchPhase III trialsIII trialsMulti-institutional phase III trialVascular endothelial growth factor receptor tyrosine kinasesEarly clinical trialsRenal cell carcinomaManagement of RCCVEGF-TKICell carcinomaClinical trialsTargeted therapyTreatment paradigmMultikinase inhibitorClinical dataFurther trialsGrowth factor receptor tyrosine kinaseTivozanibDisease settingsClinical toolReceptor tyrosine kinasesTrialsRCCTherapyTyrosine kinaseCarcinoma